Biotech | April 04, 2022
Merck expands manufacturing facility in Virginia to increase HPV vaccine supply
Supply increase to help meet growing global demand
Supply increase to help meet growing global demand
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
This collaboration strengthens Akron’s portfolio of off-the-shelf gene-editing technologies while broadening Vor Bio’s collection of nucleases to engineer gene-modified cell therapies
The study was published recently in Genome Medicine, a leading international journal focused on translational, genomic-based medicine
The scope of supply includes the skid-mounted plant as well as on-site installation and commissioning support
The expansion makes Exothera one of the largest viral vector facilities in Europe
Sputnik Light is the first component of Sputnik V
The facility will produce 150 million vaccine doses per year
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Subscribe To Our Newsletter & Stay Updated
